Engineered donor cells take on lymphoma in early trial

NCT ID NCT04288726

First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This early-phase study tests a new approach for patients with certain lymphomas (Hodgkin, NK/T-cell, and others) that have returned or not responded to treatment. The therapy uses immune cells from healthy donors that are specially trained in the lab to attack cancer cells carrying a protein called CD30, and also to target the Epstein-Barr virus if present. The main goals are to find the safest dose and to see if the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
donor immune cells (T cells) engineered to recognize CD30 and Epstein-Barr virus
What this could lead to
If it works, this could offer a new treatment option for patients with lymphomas that have not responded to standard therapy.
What could go wrong
This is a very early phase 1 trial with only 18 participants, so it is not yet known if the treatment is safe or effective. There are risks of serious side effects, including allergic reactions and graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Houston Methodist Hospital

    RECRUITING

    Houston, Texas, 77030, United States

  • Texas Children's Hospital

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.